No Detail Found!

Radiosynthesis and clinical evaluation of Ga-DOTANOC as somatostatin receptor positive benign sub-dural meningioma PET imaging agent

Author(s)
Rashid Rasheed Department of Chemistry, Government College University,Faisalabad,Pakistan;Department of Nuclear Medicine, Kuwait Cancer Control Center,Showaikh,Kuwait
Sharjeel Usmani Department of Nuclear Medicine, Kuwait Cancer Control Center,Showaikh,Kuwait
Fareeda Al-Kandari Department of Nuclear Medicine, Kuwait Cancer Control Center,Showaikh,Kuwait
Asim Mansha Department of Chemistry, Government College University,Faisalabad,Pakistan
Zahid Farooq Department of Physics, Division of Science and Technology, University of Education,Lahore,Pakistan
Syed Ali Raza Naqvi Department of Chemistry, Government College University,Faisalabad,Pakistan
Abstract
Nuclear medicine technique is a unique technique to diagnose and treat infectious and cancerous diseases at cellular or even at molecular level with great sensitivity and accuracy. Receptor positive tumors are diagnosed and treated with positron/beta-particle emitter radionuclide labeled somatostatin peptides with awesome outcome and the patient get relief in short time. DOTANOC is somatostatin hormone analogue of eight amino acid having promising affinity for somatostatin receptor positive malignancies. This study was to follow up neuroendocrine tumor suppression which also indicated the up-taking of gallium-68 (68Ga) labeled DOTANOC by benign sub-dural meningioma. Regarding labeling yield, high performance liquid chromatography analysis showed 99.17 ± 0.34% radiochemical purity. Radiochemical stability in reaction mixture and blood serum was found quite stable up to 4 h. Biodistribution study revealed that radiochemical does not accumulate at non-target sites. Kidneys showed 8.17 ± 0.76 % ID/g-organ accumulation. PET/CT scintigraphy showed in addition to follow up regular tumors therapy, the agent can also accumulate at SStR positive benign sub-dural meningioma.
Publication Details
Page(s) 1277-1280
Published Journal: Pakistan Journal of Pharmaceutical Sciences, Volume: 33, Issue: SUP3, Year: 2020

Request the full text from PASTIC

Keywords
PET-CT imaging, radiopharmaceuticals, Meningioma, 68Gallium-DOTANOC, NETs
References
Baum RP,Kulkarni HR,Singh A,Kaemmerer D,Mueller D,Prasad V,Hommann M,Robiller FC,Niepsch K,Franz H,Jochems A,Lambin P,Hörsch D P .2018 .Results and adverse events of personalized peptide receptor radionuclide therapy with (90)Yttrium and (177)Lutetium in 1048 patients with neuroendocrine neoplasms. Oncotarget, 9(24) : 16932-16950.
Becker JC,Stang A,DeCaprio JA,Cerroni L,Lebbé C,Veness M,Nghiem P .2017 .Merkel cell carcinoma. Nat. Rev. Dis. Primers, 3 : 17077-17077.
Das T,Bhadwal M,Banerjee S,Sarma HD,Shinto A,Kamaleshwaran KK .2014 .Preparation of DOTATATE and DOTA-NOC freeze-dried kits for formulation of patient doses of 177Lu-labeled agents and their comparison for peptide receptor radionuclide therapy application. J. Radioanal. Nucl. Chem, 299(1) : 1389-1398.
Leisser A,Lukic K,Nejabat M,Wadsak W,Mitterhauser M,Mayerhöfer M,Karnaikas G,Raderer M,Hacker M,Haug AR M .2019 .Sex-differences in [68Ga]GaDOTANOC biodistribution. Nucl. Med, : 15-20.
Moriyama S,Takeshita H,Araki S,Tokairin T,Kagawa M,Chiba K,Adachi A,Noro A .2016 .Carcinomalike nonfunctional pheochromocytoma in the right adrenal gland: A case report. Oncol Lett, 12(2) : 1489-1492.
Mueller D,Breeman WAP,Klette I,Gottschaldt M,Odparlik A,Baehre M,Tworowska I,Schultz MK .2016 .Radiolabeling of DOTA-like conjugated peptides with generator-produced (68)Ga and using NaCl-based cationic elution method. Nat. Protoc, 11(6) : 1057-1066.
Naqvi SAR,Yameen M,Hussain Z,Asim S,Usman M,Khan NH,Abbas K NH .2018 .Enzymatic degradation study of 111In-labeled minigastrin peptides using cathepsin B enzyme and AR42J cancer cell line for the development of neuroendocrine tumor imaging radiopharmaceuticals. Pak. J. Pharm. Sci., 31(6 Suppl.) : 2585-2589.
Reubi JC .2003 .) Peptide receptors as molecular targets for cancer diagnosis and therapy. Endocr. Rev., 24(4) : 389-427.
Rizvi SFA,Naqvi SAR,Roohi S,Sherazi TA,Rasheed R .2018 .177Lu-DOTA-coupled minigastrin peptides: promising theranostic agents in neuroendocrine cancers. Mol. Biol. Rep, 45(6) : 1759-1767.
Vis R,Lavalaye R,van de Garde EMW .2015 .GMPcompliant 68Ga radiolabelling in a conventional smallscale radiopharmacy: A feasible approach for routine clinical use. EJNMMI Research, 5 : 27.
0

Citations

0

Downloads

12

Views